Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.

The Lancet Infectious Diseases
Mainga HamalubaArjen M Dondorp

Abstract

Triple antimalarial combination therapies combine potent and rapidly cleared artemisinins or related synthetic ozonides, such as arterolane, with two, more slowly eliminated partner drugs to reduce the risk of resistance. We aimed to assess the safety, tolerability, and efficacy of arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Kenyan children. In this single-centre, open-label, randomised, non-inferiority trial done in Kilifi County Hospital, Kilifi, coastal Kenya, children with uncomplicated Plasmodium falciparum malaria were recruited. Eligible patients were aged 2-12 years and had an asexual parasitaemia of 5000-250 000 parasites per μL. The exclusion criteria included the presence of an acute illness other than malaria, the inability to tolerate oral medications, treatment with an artemisinin derivative in the previous 7 days, a known hypersensitivity or contraindication to any of the study drugs, and a QT interval corrected for heart rate (QTc interval) longer than 450 ms. Patients were randomly assigned (1:1:1), by use of blocks of six, nine, and 12, and opaque, sealed, and sequentially numbered envelopes, to receive eit...Continue Reading

References

Feb 16, 2000·Transactions of the Royal Society of Tropical Medicine and Hygiene·G SnounouS Viriyakosol
Aug 25, 2004·Science·Cally RoperTim Anderson
Apr 20, 2005·Transactions of the Royal Society of Tropical Medicine and Hygiene·Catherine FaladePatricia Ibarra de Palacios
Feb 16, 2007·Tropical Medicine & International Health : TM & IH·Elizabeth A AshleyFrançois Nosten
Jul 31, 2014·The New England Journal of Medicine·Elizabeth A AshleyUNKNOWN Tracking Resistance to Artemisinin Collaboration (TRAC)
Feb 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Offianan Andre TourePaul Swoboda
Jun 18, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aung Pyae PhyoFrancois Nosten
Mar 25, 2019·Malaria Journal·Edwin G TseMatthew H Todd
Jun 10, 2019·Trends in Parasitology·Carlo GiannangeloDarren J Creek

❮ Previous
Next ❯

Citations

Jun 26, 2021·Malaria Journal·Nicholas J White, François H Nosten
Jul 17, 2021·Current Opinion in Infectious Diseases·Mehul DhordaArjen M Dondorp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.